Minority Enrollment in Phase II and III Clinical Trials in Urologic Oncology.
Jeunice Owens-WaltonCheyenne WilliamsAlexis Rompre-BrodeurPeter A PintoMark W. BallPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Clinical trials targeting prostate, kidney, and bladder cancers continue to under-represent racial/ethnic minority patients. On the basis of the incidence of these cancers within minority populations, efforts should focus on creating racially and ethnically inclusive cancer research.
Keyphrases
- clinical trial
- phase ii
- open label
- end stage renal disease
- prostate cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- double blind
- spinal cord injury
- risk factors
- prognostic factors
- papillary thyroid
- peritoneal dialysis
- squamous cell carcinoma
- childhood cancer
- study protocol
- healthcare
- randomized controlled trial
- placebo controlled
- young adults
- patient reported outcomes
- benign prostatic hyperplasia